To expand Xyrem’s addressable market, JAZZ has been evaluating the efficacy of Xyrem in pediatric narcolepsy patients with cataplexy and excessive sleepiness.
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.
For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%.
On August 3, JAZZ managed to secure regulatory approval from the FDA for its innovative drug, Vyxeos, as a treatment option for two types of acute myeloid leukemia.
JAZZ is now engaged in patent litigations involving Xyrem in the US with four other generic players.
Medtronic (MDT) will announce its fiscal 1Q18 results on August 2, 2017.
For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.
In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.
In fiscal 4Q17, Medtronic’s revenue came in at $7.9 billion, representing YoY (year-over-year) growth of ~5%.
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
In 2Q17, Orencia contributed around 13% of Bristol-Myers Squibb’s net revenues.
In the Phase 3 CheckMate-214 trial, 41.6% patients on Opdivo and Yervoy combination therapy achieved the objective response rate (or ORR) compared to 26.5% patients who were on sunitinib.
In June 2017, Bristol-Myers Squibb presented the clinical trial data of its Phase 1/2 ECHO-204 trial.
In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.
In 2Q17, Bristol-Myers Squibb reported diluted earnings per share (or EPS) of $0.56 compared to $0.69 in 2Q16.
Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”
In addition to selling dialysis products, Fresenius Medical Care also offers dialysis treatment and associated laboratory services to patients through its network of 3,690 clinics.
For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s net profit margins to be close to 6.2%, which is a YoY decline of ~70 basis points.
In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.
In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.